KR20200084320A - 공유 항원을 표적으로 하는 항원-결합 단백질 - Google Patents

공유 항원을 표적으로 하는 항원-결합 단백질 Download PDF

Info

Publication number
KR20200084320A
KR20200084320A KR1020207007862A KR20207007862A KR20200084320A KR 20200084320 A KR20200084320 A KR 20200084320A KR 1020207007862 A KR1020207007862 A KR 1020207007862A KR 20207007862 A KR20207007862 A KR 20207007862A KR 20200084320 A KR20200084320 A KR 20200084320A
Authority
KR
South Korea
Prior art keywords
seq
hla
abp
sequence
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207007862A
Other languages
English (en)
Korean (ko)
Inventor
조슈아 마이클 프란시스
기스베르트 마르닉스 그로텐브레그
카린 주스
웨이드 블레어
브렌던 불릭-술리반
제니퍼 버스비
미셸 앤 버스비
모카 스코베르네
로만 엘렌스키
Original Assignee
그릿스톤 온콜로지, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 그릿스톤 온콜로지, 인코포레이티드 filed Critical 그릿스톤 온콜로지, 인코포레이티드
Priority to KR1020257008027A priority Critical patent/KR20250040097A/ko
Publication of KR20200084320A publication Critical patent/KR20200084320A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001191—Melan-A/MART
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • G01N33/57492—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hospice & Palliative Care (AREA)
KR1020207007862A 2017-08-18 2018-08-17 공유 항원을 표적으로 하는 항원-결합 단백질 Ceased KR20200084320A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257008027A KR20250040097A (ko) 2017-08-18 2018-08-17 공유된 항원을 표적화하는 항원-결합 단백질

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762547146P 2017-08-18 2017-08-18
US62/547,146 2017-08-18
US201762581368P 2017-11-03 2017-11-03
US62/581,368 2017-11-03
PCT/US2018/046997 WO2019036688A1 (en) 2017-08-18 2018-08-17 ANTIGEN BINDING PROTEINS TARGETING SHARED ANTIGENS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257008027A Division KR20250040097A (ko) 2017-08-18 2018-08-17 공유된 항원을 표적화하는 항원-결합 단백질

Publications (1)

Publication Number Publication Date
KR20200084320A true KR20200084320A (ko) 2020-07-10

Family

ID=65362959

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207007862A Ceased KR20200084320A (ko) 2017-08-18 2018-08-17 공유 항원을 표적으로 하는 항원-결합 단백질
KR1020257008027A Pending KR20250040097A (ko) 2017-08-18 2018-08-17 공유된 항원을 표적화하는 항원-결합 단백질

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257008027A Pending KR20250040097A (ko) 2017-08-18 2018-08-17 공유된 항원을 표적화하는 항원-결합 단백질

Country Status (12)

Country Link
US (2) US20210147550A1 (https=)
EP (1) EP3668539A4 (https=)
JP (1) JP2021500852A (https=)
KR (2) KR20200084320A (https=)
CN (2) CN121517566A (https=)
AU (1) AU2018318303A1 (https=)
CA (1) CA3072816A1 (https=)
IL (1) IL272466A (https=)
MX (2) MX2020001879A (https=)
SG (1) SG11202001368SA (https=)
WO (1) WO2019036688A1 (https=)
ZA (1) ZA202001285B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022010274A1 (ko) 2020-07-08 2022-01-13 주식회사 엘지에너지솔루션 배터리 팩, 및 이를 포함하는 자동차

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
MA49156A (fr) 2014-12-23 2020-03-25 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
US9422547B1 (en) 2015-06-09 2016-08-23 Gigagen, Inc. Recombinant fusion proteins and libraries from immune cell repertoires
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
EP3731876A4 (en) * 2017-12-28 2022-04-06 Gritstone bio, Inc. ANTIGEN-BINDING PROTEINS TARGETING SHARED ANTIGENS
WO2019204683A1 (en) * 2018-04-19 2019-10-24 Board Of Regents, The University Of Texas System T cell receptors with mage-b2 specificity and uses thereof
WO2020037302A1 (en) * 2018-08-17 2020-02-20 Gritstone Oncology, Inc. Antigen-binding proteins targeting shared antigens
CN111138522B (zh) * 2018-11-06 2023-01-24 香雪生命科学技术（广东）有限公司 衍生自afp的肿瘤抗原短肽
CN111138521B (zh) * 2018-11-06 2022-10-28 香雪生命科学技术（广东）有限公司 源自于afp抗原的短肽
CN114026116A (zh) * 2019-02-20 2022-02-08 弗雷德哈钦森癌症研究中心 Ras新抗原特异性结合蛋白及其用途
WO2020191365A1 (en) * 2019-03-21 2020-09-24 Gigamune, Inc. Engineered cells expressing anti-viral t cell receptors and methods of use thereof
EP3714941A1 (en) * 2019-03-27 2020-09-30 Medigene Immunotherapies GmbH Mage-a4 tcrs
US20200318068A1 (en) * 2019-04-04 2020-10-08 Immatics US, Inc. Use of retinoic acid in t-cell manufacturing
WO2020206238A2 (en) 2019-04-05 2020-10-08 Rootpath Genomics, Inc. Compositions and methods for t-cell receptor gene assembly
EP3962939A4 (en) * 2019-05-03 2023-05-17 Gigamune, Inc. MODIFIED CELLS EXPRESSING ANTITUMOR T-LYMPHOCYTE RECEPTORS AND METHODS OF USING THEM
CA3139011A1 (en) 2019-05-08 2020-11-12 Medigene Immunotherapies Gmbh Engineered t cells
BR112021023345A2 (pt) 2019-05-20 2022-02-01 Pandion Operations Inc Imunotolerância com alvo em madcam
EP3760217A1 (en) * 2019-07-01 2021-01-06 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Cd5 specific t cell receptor cell or gene therapy
KR20220052910A (ko) * 2019-07-09 2022-04-28 메디진 이뮤노테라피스 게엠바하 Ｍａｇｅａ10 특이적 ｔ 세포 수용체 및 이의 용도
KR20240137107A (ko) 2019-07-16 2024-09-19 길리애드 사이언시즈, 인코포레이티드 Hiv 백신, 및 이의 제조 및 사용 방법
CN112300261B (zh) * 2019-07-23 2023-03-17 香雪生命科学技术（广东）有限公司 一种衍生自afp的肿瘤抗原短肽
BR112022003163A2 (pt) * 2019-08-19 2022-05-17 Pandion Operations Inc Imunotolerância alvejada com um agonista de pd-1
WO2021048381A1 (en) * 2019-09-13 2021-03-18 Evaxion Biotech Aps Method for identifying stable mhc binding peptides using mass spectrometry
US20220372092A1 (en) * 2019-10-18 2022-11-24 Board Of Regents, The University Of Texas System Hla-restricted vcx/y peptides and t cell receptors and use thereof
WO2021092094A1 (en) * 2019-11-04 2021-05-14 Gritstone Oncology, Inc. Antigen-binding proteins targeting shared neoantigens
KR20220098379A (ko) * 2019-11-15 2022-07-12 그릿스톤 바이오, 인코포레이티드 공유 네오항원을 표적으로 하는 항원-결합 단백질
CN112898399A (zh) * 2019-12-03 2021-06-04 香雪生命科学技术（广东）有限公司 源自于afp抗原的短肽
CN115960206A (zh) * 2019-12-13 2023-04-14 南京大户生物科技有限公司 原发性肝癌相关抗原的胸腺依赖性淋巴细胞抗原表位肽及其应用
CN113072636B (zh) * 2020-01-06 2024-05-28 香雪生命科学技术（广东）有限公司 一种识别afp的t细胞受体及其编码序列
EP4107187A4 (en) 2020-02-21 2024-07-03 Pandion Operations, Inc. TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
CN113321725B (zh) * 2020-02-28 2024-06-11 香雪生命科学技术（广东）有限公司 一种识别afp的t细胞受体
CN113321727B (zh) * 2020-02-28 2024-04-09 香雪生命科学技术（广东）有限公司 一种识别afp抗原短肽的t细胞受体及其编码序列
BR112022017924A2 (pt) * 2020-03-10 2022-12-20 Massachusetts Inst Technology Composições e métodos para imunoterapia de câncer npm1c-positivo
JP2023517063A (ja) * 2020-03-10 2023-04-21 マサチューセッツ インスティテュート オブ テクノロジー 操作されたメモリー様ｎｋ細胞を作製するための方法およびその組成物
CN113493505A (zh) * 2020-03-20 2021-10-12 香雪生命科学技术（广东）有限公司 识别afp抗原的高亲和力tcr
CN113621070A (zh) 2020-05-06 2021-11-09 华夏英泰（北京）生物技术有限公司 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用
AU2021276264A1 (en) * 2020-05-18 2022-12-22 Board Of Regents, The University Of Texas System Engineered T cell receptors and methods of use
CA3183756A1 (en) 2020-05-19 2021-11-25 Amgen Inc. Mageb2 binding constructs
WO2021252517A1 (en) * 2020-06-09 2021-12-16 Board Of Regents, The University Of Texas System Engineered t cell receptors and methods of use
US20240059797A1 (en) * 2020-07-29 2024-02-22 Gritstone Bio, Inc. Engineered multi-specific antibodies and related methods of use and manufacture
TWI900647B (zh) * 2020-09-04 2025-10-11 美國衛生與公眾服務部 識別p53中r273c或y220c突變的t細胞受體
BR112023005296A2 (pt) * 2020-09-24 2023-04-25 Medigene Immunotherapies Gmbh Receptores de células t específicos de mage-a3 e uso dos mesmos
MX2023003372A (es) * 2020-09-24 2023-05-04 Medigene Immunotherapies Gmbh Nuevos receptores prame y usos de los mismos.
AU2021366741A1 (en) * 2020-10-23 2023-05-11 Rootpath Genomics, Inc. Compositions and methods for t-cell receptor identification
JP2023548556A (ja) * 2020-11-05 2023-11-17 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｅｇｆｒ抗原を標的とする操作されたｔ細胞受容体および使用方法
WO2022155503A1 (en) * 2021-01-14 2022-07-21 Gritstone Bio, Inc. Multi-specific antibodies and methods of use
US12053517B2 (en) 2021-01-14 2024-08-06 Gilead Sciences, Inc. HIV vaccines and methods of using
WO2022177961A1 (en) * 2021-02-16 2022-08-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class i–restricted t cell receptors against cd22
US12435444B2 (en) 2021-03-09 2025-10-07 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
MX2023010541A (es) 2021-03-09 2023-11-24 Cdr Life Ag Proteinas de union al antigeno del peptido del mhc mage-a4.
KR20240005714A (ko) * 2021-03-29 2024-01-12 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Sars-cov-2 항원을 표적화하는 펩티드 및 조작된 t 세포 수용체 및 사용 방법
WO2022216574A1 (en) * 2021-04-05 2022-10-13 Janssen Biotech, Inc. Calr and jak2 t-cell receptors
WO2022229966A1 (en) 2021-04-29 2022-11-03 Yeda Research And Development Co. Ltd. T cell receptors directed against ras-derived recurrent neoantigens and methods of identifying same
EP4091627A1 (en) * 2021-05-21 2022-11-23 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Tcr constructs specific for magea4-derived epitopes
CN117545766A (zh) * 2021-05-25 2024-02-09 纪念斯隆-凯特琳癌症中心 靶向ras突变的t细胞受体及其用途
KR20240045239A (ko) * 2021-08-06 2024-04-05 안야디, 엘엘씨 개인 맞춤형 암 면역치료제 제조방법
WO2023050063A1 (zh) * 2021-09-28 2023-04-06 溧阳瑅赛生物医药有限公司 一种识别hla-a*02:01/e629-38的tcr及其应用
EP4422651A4 (en) * 2021-10-25 2025-12-17 Univ Texas PEPTIDES AND MANIPULATED T-CELL RECEPTORS FOR TARGETTING THE MAGE-A4 ANTIGEN AND METHOD FOR USE
JP2024540197A (ja) * 2021-10-29 2024-10-31 ホウ，ヤフェイ Ｐ５３におけるｒ１７５ｈ変異を認識するｔ細胞受容体およびその用途
EP4472742A1 (en) * 2022-02-03 2024-12-11 University College Cardiff Consultants Limited Novel t-cell receptor
CA3244259A1 (en) * 2022-02-23 2023-08-31 Aloe Therapeutics Inc Compositions and methods for modulating the immune system
NL2031118B1 (en) * 2022-03-01 2023-09-07 Academisch Ziekenhuis Leiden T cell receptors directed against transcription factor wt1 and uses thereof
CN116836261A (zh) * 2022-03-24 2023-10-03 香雪生命科学技术（广东）有限公司 一种识别mage-a4抗原的高亲和力tcr及其序列和应用
CN117264043B (zh) * 2022-06-14 2024-05-10 上海镔铁生物科技有限责任公司 靶向kras g12v突变多肽的t细胞受体及其用途
CA3264474A1 (en) 2022-09-14 2024-03-21 Cdr-Life Ag MAGE-A4 DOUBLE T LYMPHOCYTE ENGAGEMENT
EP4598569A1 (en) * 2022-10-05 2025-08-13 Tscan Therapeutics, Inc. Magea1 immunogenic peptides, binding proteins recognizing magea1 immunogenic peptides, and uses thereof
CN116158405B (zh) * 2023-01-30 2024-04-26 西北农林科技大学 一种提高奶山羊后代母羔率的方法
WO2025064738A1 (en) * 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Dntt 250-258 off-target peptides and uses thereof
AU2024374117A1 (en) * 2023-10-30 2026-04-09 T-Knife Gmbh Antigen-recognizing construct capable of binding to a frame peptide and a t cell receptor
CN118256604B (zh) * 2024-04-16 2024-11-19 华中科技大学 一种利用人工抗原呈递细胞进行免疫原性肿瘤新抗原筛选与鉴定方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030017134A1 (en) * 2001-06-19 2003-01-23 Technion Research And Development Foundation Ltd. Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
AU2003216341A1 (en) * 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
CA2742969A1 (en) * 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
AU2012309830B2 (en) * 2011-09-15 2017-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing HLA-A1- or HLA-Cw7-restricted mage
HK1205686A1 (en) * 2012-02-29 2015-12-24 Ambrx, Inc. Novel prodrug containing molecule compostions and their uses
TWI702229B (zh) * 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
TW201702272A (zh) * 2015-05-22 2017-01-16 美國紀念斯隆 凱特琳癌症中心 Ｐｒａｍｅ肽專一性類ｔ細胞受體抗體
GB201520559D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
CN109069627A (zh) * 2016-01-14 2018-12-21 纪念斯隆-凯特琳癌症中心 对foxp3衍生肽特异性的t细胞受体样抗体

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022010274A1 (ko) 2020-07-08 2022-01-13 주식회사 엘지에너지솔루션 배터리 팩, 및 이를 포함하는 자동차

Also Published As

Publication number Publication date
US20210147550A1 (en) 2021-05-20
WO2019036688A1 (en) 2019-02-21
JP2021500852A (ja) 2021-01-14
CN111328288B (zh) 2025-11-07
KR20250040097A (ko) 2025-03-21
CA3072816A1 (en) 2019-02-21
MX2020001879A (es) 2020-07-29
AU2018318303A1 (en) 2020-04-09
MX2025011582A (es) 2025-11-03
EP3668539A1 (en) 2020-06-24
US20230382997A1 (en) 2023-11-30
SG11202001368SA (en) 2020-03-30
CN121517566A (zh) 2026-02-13
ZA202001285B (en) 2021-08-25
IL272466A (en) 2020-03-31
EP3668539A4 (en) 2021-08-18
CN111328288A (zh) 2020-06-23

Similar Documents

Publication Publication Date Title
US20230382997A1 (en) Antigen-binding proteins targeting shared antigens
TWI837109B (zh) 靶向共有抗原之抗原結合蛋白
CN112739375B (zh) 靶向共同抗原的抗原结合蛋白
US20220162320A1 (en) Multispecific binding proteins
EP4188962A1 (en) Engineered multi-specific antibodies and related methods of use and manufacture

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000